Pediapharm Inc. (TSXV:PDP) has infrastructure in place to grow their expected revenue to $40 million

Pediapharm
Inc. (TSXV: PDP), which focuses on children’s medicine, plans to launch
five new products during the next 18 months, says President and CEO
Sylvain Chretien. These new offerings are expected to boost Pediapharm’s
revenue significantly over the next
year and a half, and Mr. Chretien describes how his Company’s business
model differs from that of Valiant.
“To See More….”